Reduces the risk of disease progression by 40% FDA approves Sanofi CD38 antibody for marketing

On the 3rd, the US FDA announced the approval of the listing of the CD38 antibody Sarclisa (isatuximab-irfc) developed by Sanofi (Sanofi) for use in combination with pomalidomide and dexamethasone to